Teladoc Health Inc. (TDOC) Dividend Safety Gauge & 10-Year DRIP Compounder

Per the Roarable RQD rating, TDOC scores 56 out of 100, equating to a D+ grade and the verdict "Roarable Sell — Weak Fundamentals / Trim." The five pillars are: Fundamental Cash Engine at 6 of 20 (ROIC of -17%; FCF yield of 18%), Whale 13F Flow at 16 of 20 (institutional accumulation and options positioning), Insider Conviction at 13 of 20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 11 of 20 (Beta 1.08; sector sensitivity), and Forensic Balance Sheet at 10 of 20 (Altman Z 0.45; Piotroski F 7/9; Debt/Equity 0.45).

The weakest pillar is the Fundamental Cash Engine, which is consistent with negative ROIC and negative operating margin. The strongest pillar is Whale 13F Flow, though the source data for holders is not available, so the pillar score cannot be traced to specific filings in this dossier. For a prospective investor, the rating points to weak operating economics as the central tradeoff: the reported FCF yield of 18% contrasts with negative net and operating margins, and the valuation case depends on whether that cash generation can be sustained. The Forward P/E of 32 against EPS (TTM) of -1.1 means the market is pricing future earnings that the trailing record does not yet show. The Altman Z of 0.45 and Piotroski F of 7/9 point to a distressed-zone solvency reading alongside a relatively healthy internal scoring, which investors should weigh together rather than in isolation. The most recent reported price move of 26.89% sits near the top of the 52-week range of $4.4 - $9.89, which the rating does not interpret.

Per the SEC financials, reported revenue declined modestly across the three periods while operating and net losses persisted in each, with FY 2024 showing the largest net loss. Per the market data, net margin is -7.9%, operating margin is -10.4%, and gross margin is 0%, and ROIC is -17%. Per the Roarable RQD rating, the Altman Z-Score is 0.45 and the Piotroski F-Score is 7/9, with Debt/Equity at 0.45. Reported cash declined from $1298.3M in FY 2024 to $781.1M in FY 2025, and debt declined from $911.5M to $662.7M over the same span.

• What is the source of the reported 18% FCF yield given negative operating and net income in each period?
• What drove the 26.89% price change, and is there any catalyst documented for it?
• What are the components of the Forward P/E of 32 and the basis for the consensus earnings expectation behind it?
• Which institutional holders and insider transactions underlie the Whale 13F and Insider Conviction pillar scores?
• What is the company's revenue mix and customer concentration, which the source data does not describe?